Compass Pathways

COMPASS Pathways (NASDAQ:CMPS), a key player in the psychedelics industry, recently experienced a $43 million drop in market capitalization, reducing its value to $302 million. As Simply Wall St. reported, this decline has placed institutional investors, who own 30% of the company's shares, under...

Compass Pathways (NASDAQ:CMPS) has announced delays for two key Phase 3 clinical trials involving its psilocybin program, widely seen as a leader in the psychedelic drug development space. As Endpoint News reported, the unexpected timeline shifts, unveiled in the company's third-quarter earnings...

A groundbreaking study from New York’s Columbia University suggests that psilocybin, the psychoactive compound in magic mushrooms may offer relief to individuals suffering from body dysmorphic disorder (BDD). The research, published in Psychedelics, explored the effects of psilocybin on brain...

The U.S. Food and Drug Administration (FDA) has issued a complete response letter for MDMA-assisted psychotherapy (MDMA-AT) for treating post-traumatic stress disorder (PTSD) in which it calls for an additional phase 3 trial to further evaluate its safety and efficacy. As Psychiatric Times...

The global psychedelic drugs market is poised for significant growth over the next five years, with an estimated increase of USD 1.37 billion from 2024 to 2028, according to a report by Technavio. The market is projected to grow at a compound annual growth rate (CAGR) of 11.82%, fueled by the...

The American Medical Association’s new coverage and reimbursement codes for FDA-legalized psychedelic-assisted therapies, the current procedural terminology (CPT) III codes, have become active for physicians and other qualified healthcare providers to apply. These are temporary codes assigned...

Recent advancements in understanding mental health and the brain have allowed us to identify possible commonalities between different mental health conditions. One of the shared experiences among patients with conditions like treatment-resistant depression (TRD), bipolar II disorder and PTSD is the...

Artificial Intelligence (AI) is rapidly penetrating a number of different sectors, including healthcare. The use of AI in mental health has opened up the possibility of new avenues of care, potentially allowing for more efficient diagnosis, treatment and patient care. Machine learning algorithms...

Treatment-resistant depression, also referred to as TRD, is a subset of depression that poses significant challenges for clinicians, patients and those closest to patients. It is characterized by persistent symptoms of depression that do not respond adequately to at least two different standard...

In August, a group of well-known biotech institutional investors participated in an up to almost $300 million financing round for COMPASS Pathways (NASDAQ: CMPS), consisting of an initial investment of $125 million and the potential for an additional investment of up to $160 million if the...

The American Medical Association (AMA) published language concerning the recently-approved Current Procedural Terminology (CPT) III codes applying to psychedelic-assisted therapies, as announced by its forwarders the MAPS Public Benefit Corporation and COMPASS Pathways (NASDAQ: CMPS)....

Psychedelic Therapy Now Available As Workplace Benefit, Free Month For Laid-Off Tech Workers Psychedelic healthcare insurance plans provider Enthea announced it will launch its services into 40 markets across the US in 2023 with the idea of making psychedelic-assisted therapies affordable,...

(Part four of a four-part series) See previous stories:  Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS' Latest Trial Outcomes Psychedelics And Treatment-Resistant Depression: Reactions To COMPASS' Published Results Psychedelics And Treatment-Resistant...

Psilocybin is known as the active compound in so-called “magic mushrooms”, yet most psilocybin used in clinical trials today is synthesized in laboratories without the use of biological material. As psychedelics-assisted therapy gains momentum, investors need to understand the...

Two companies in the psychedelics space have chosen new chief executive officers: COMPASS Pathways (NASDAQ: CMPS) has chosen Kabir Nath, and Small Pharma will be now led by George Tziras. Compass Pathways Adds Kabir Nath On Board Nath will effectively become chief executive officer...